Platelet-Rich Plasma: The Science of Dosing and Healing

Platelet-Rich Plasma: Precision Dosing and Healing

Abstract

As a clinician and researcher dedicated to integrative and functional medicine, I am constantly exploring the most effective, evidence-based treatments for my patients. Platelet-Rich Plasma (PRP) therapy stands out as a powerful tool in regenerative medicine, particularly for musculoskeletal conditions. However, not all PRP is created equal. In this educational post, I will take you on a journey through the intricate world of PRP, drawing from the latest findings of leading researchers. We will explore the fundamental biology of platelets, dissect the critical importance of PRP dosing and formulation, and examine how factors such as age and the presence of other cells, including white blood cells, can dramatically influence treatment outcomes. I will also explain how we calculate and customize these treatments in a clinical setting, and how integrating these advanced biological therapies with foundational care, such as integrative chiropractic, can optimize healing and provide a comprehensive path to recovery.

Understanding the Foundation: What Are Platelets?

To truly appreciate the power of PRP therapy, we first need to revisit a fundamental concept from our early medical training: the platelet. These are not complete cells but rather tiny, anucleated (lacking a nucleus) cell fragments that circulate in our blood. Despite their small size, they are biological powerhouses, densely packed with hundreds of proteins, growth factors, and cytokines essential for healing.

Platelets have a relatively short lifespan of about seven to ten days. This is a crucial piece of information, especially when I advise patients to restrict the use of non-steroidal anti-inflammatory drugs (NSAIDs) before a procedure, as these medications can interfere with platelet function.

In a healthy individual, the typical platelet count ranges from 150,000 to 400,000 per microliter of blood. The FDA’s definition of PRP is somewhat broad, simply stating it’s a concentration of platelets above this normal baseline. Our goal with PRP therapy is to harness the body’s innate healing capacity by concentrating these vital platelets and their associated growth factors and then delivering this potent biological product precisely to an area of injury or degeneration. This targeted delivery initiates and amplifies the body’s natural healing cascade.

The Critical Issue of Variability in PRP Preparations

While the concept of PRP is straightforward, the execution is anything but. There is significant variability among commercially available systems for preparing PRP, which can lead to markedly different clinical outcomes. This isn’t just a minor detail; it’s at the core of whether a treatment succeeds or fails.

A pivotal study from Australia by James and colleagues (2016) examined five different commercial PRP systems and found dramatic differences in both the final platelet concentration and the number of white blood cells included in the final product. Imagine the same patient’s blood being processed through four different systems. The resulting PRP can range in color from light straw-yellow to deep red, each color representing a different cellular composition. This “rainbow” of PRP products highlights the lack of standardization in the field.

This variability has significant implications for our evaluation of the scientific evidence. For years, colleagues and patients have asked about the evidence supporting PRP. A landmark meta-analysis by Meheux et al. (2016) revealed something fascinating: more patients have been enrolled in clinical trials for PRP for knee osteoarthritis (OA) than for other common treatments like hyaluronic acid injections. The data exists, but the variability in results often stems from the variability in the PRP product used. Generally, high-quality studies show that PRP therapy tends to outperform hyaluronic acid in the medium- to long-term.

How We Create a Therapeutic PRP Product in Our Clinic

So, how do we create this biologic therapy? The process begins with a simple blood draw right here in the office. The amount of blood we draw is a critical first step—less blood means fewer total platelets to start with, while a larger volume gives us more raw material to create a higher-dose product.

1. Blood Draw: We draw a specific volume of the patient’s whole blood into a specialized, sterile, closed-system kit.
2. First Centrifugation (Hard Spin): The kit is placed in a centrifuge, a machine that spins at high speeds. This initial spin separates the blood into distinct layers based on density. The heavier red blood cells settle at the bottom, a thin, whitish layer called the “buffy coat” forms in the middle, and the lighter, platelet-poor plasma rises to the top. The buffy coat is rich in both platelets and white blood cells.
3. Isolation: The magic happens in how we isolate these layers. In the system I use, a “hard spin” process creates a very concentrated buffy coat. We then carefully separate the platelet-rich plasma and buffy coat from the red blood cells and platelet-poor plasma.
4. Second Centrifugation (Soft Spin): Some systems use a two-spin process. After the initial separation, the platelet-rich plasma is spun again to further concentrate the platelets into a smaller volume.
5. Extraction: Precision is key during extraction. In the system we use, we know that approximately 85% of the platelets are concentrated within a tiny two-millimeter layer. This allows us to extract a very high platelet concentration in a small, injectable volume.

Understanding the specific mechanics of your chosen system is paramount to maximizing the therapeutic potential of the PRP you deliver to your patients.

The Concept of Clinical Dosing: Why More Isn’t Always Better

Although the FDA doesn’t regulate PRP as a drug with specific dosage requirements, we must consider it a biologic drug. Like any medication, there is a therapeutic dose-response curve. A dose that is too low (subtherapeutic) will fail to produce a biological effect, while an excessively high dose can, in some cases, have an inhibitory or even detrimental effect.

• Under-dosing: Fails to trigger the desired healing response.
• Therapeutic Dosing: Hits the “sweet spot” to optimize cellular regeneration.
• Over-dosing: Can potentially inhibit the very cells we are trying to stimulate.

Research has begun to clarify what these therapeutic doses might be. For tendon injuries, studies have shown an optimal platelet concentration that best stimulates tenocyte (tendon cell) regeneration. As you go above that optimal concentration, you can actually see a decrease in tenocyte proliferation (Giusti et al., 2009). This highlights that simply aiming for the highest possible concentration isn’t the right strategy.

Dosing for Soft Tissue and Tendon Injuries

So, what is the right clinical dose? The answer varies by the tissue we are treating. A groundbreaking study by Peter Everts’ group examined various soft-tissue applications of PRP (Everts et al., 2020). They meticulously calculated the total platelet dose administered in numerous published studies and correlated it with clinical outcomes.

The results were striking. They found a clear threshold. Studies with total platelet doses below 3.5 billion platelets were overwhelmingly negative. In contrast, studies using a dose above 3.5 billion platelets were predominantly positive. This suggests a therapeutic threshold for soft tissue applications. If your PRP system can only produce, say, 1.5 billion platelets from a standard blood draw, you may be consistently under-dosing your patients and seeing disappointing results.

Further research from Scott Rodeo’s group at the Hospital for Special Surgery reinforced this dose-dependent effect, showing that studies using higher-dose PRP reported significantly better outcomes (Cole et al., 2021). The emerging consensus is that for many soft-tissue and tendon injuries, a platelet dose of 3.5 to 10 billion platelets is likely necessary to achieve a robust clinical effect.

The Influence of Age and How We Adapt

Another critical factor we must consider is the patient’s age. As we age, the regenerative capacity of our cells can decline. Emerging evidence suggests that older patients may require a higher total dose of PRP to achieve the same therapeutic effect as a younger patient. In my clinical practice, this means I might opt for a larger initial blood draw for an older individual to ensure we can generate a sufficiently potent PRP product. We are still in the early stages of understanding these nuances, but personalizing treatment based on patient factors such as age is a cornerstone of effective biologic therapy.

Dosing for Knee Osteoarthritis: A Case Study in Getting It Right

Knee osteoarthritis (OA) is one of the most-studied applications for PRP, and it provides an excellent case study in the importance of dosing. The well-known RESTORE trial, published in JAMA, initially concluded that PRP was not effective for knee OA (Bennell et al., 2021). However, when you dig into the methodology, you find the issue: they used a low-dose PRP system that delivered only 1.6 billion platelets per injection. Based on our dose-response curve, this is a subtherapeutic dose, so a negative result is not surprising. While the study was impeccably conducted, it taught us a valuable lesson about the importance of using an adequate biologic dose.

In stark contrast, another widely cited study used a much higher dose of 10 billion platelets (Bansal et al., 2021). In this high-dose trial, patients not only experienced significant improvements in pain and function, but imaging studies also showed a slowing of cartilage degeneration. This suggests a potential disease-modifying effect—something we rarely see with other treatments. Other studies have found similar benefits with repeated injections totaling 5 to 15 billion platelets. For knee OA, the therapeutic target appears to be in the 5-10 billion platelet range.

Concentration vs. Dose: A Crucial Distinction

In the literature and among clinicians, you’ll often hear PRP described by its concentration, such as “2x, 3x, or 4x” baseline. This can be misleading. Imagine you have 5 billion platelets in a glass. That is your total dose. Now, if you add a lot of water (plasma), the concentration goes down, but the total number of platelets remains the same. Conversely, if you remove most of the water, the concentration increases, but the dose remains 5 billion.

I advocate for discussing and studying PRP in terms of total platelet dose (the absolute number of platelets being injected) rather than concentration. The total dose is a more accurate and reproducible measure of the biological substance being delivered. To calculate this in the clinic, you need two things: the patient’s baseline platelet count (from a CBC) and the recovery efficiency of your specific PRP system. While a baseline CBC can fluctuate, it provides a crucial starting point for individualizing treatment and ensuring we are meeting our therapeutic target.

The Role of White Blood Cells: Leukocyte-Rich vs. Leukocyte-Poor PRP

Platelets are not the only cells in the PRP mixture. The “buffy coat” also contains a significant number of leukocytes, or white blood cells (WBCs). This has led to a major debate in the field: is it better to use leukocyte-rich (LR-PRP) or leukocyte-poor (LP-PRP) formulations?

• Neutrophils: These are highly pro-inflammatory WBCs. Their presence in a PRP injection can cause a more intense, short-term inflammatory reaction, leading to more post-injection pain and swelling. In some cases, particularly within a joint capsule, the concern is that this intense inflammation could be detrimental to cartilage.
• Monocytes and Lymphocytes: These WBCs play a more constructive role in the healing process, orchestrating the transition from the inflammatory to the regenerative phase.

The data comparing LR-PRP and LP-PRP is mixed. Some studies, particularly those from outside Europe, suggest that for knee OA, there may not be a significant clinical difference in long-term outcomes, although LR-PRP often causes greater initial inflammation. My approach is to consider the injection site and the underlying pathology. For an intra-articular injection (inside a joint), I often lean towards an LP-PRP formulation to minimize the initial inflammatory flare. For a tendon injury, where a robust inflammatory signal is needed to jump-start a chronic, stagnant healing process, a leukocyte-rich formulation may be more appropriate.

Integrating Chiropractic Care for Optimal Outcomes

PRP therapy is a powerful tool, but it is not a magic bullet. To achieve the best possible outcomes, it must be integrated into a comprehensive rehabilitation plan. This is where the principles of integrative chiropractic care become indispensable.

The goal of a PRP injection is to create a biological scaffold (a clot rich in growth factors) directly at the site of tissue damage, thereby initiating a healing response. Ultrasound guidance is non-negotiable for this; we must ensure we are delivering the product precisely into the tendon tear or joint space. If the injection is off-target, the therapy will fail.

Following the procedure, the body needs the right environment to heal. This involves:

• Proper Rehabilitation: The healing process takes time, often three months or more. A structured physical therapy and rehabilitation program is essential to properly load the healing tissues, promote correct fiber alignment, and restore function.
• Chiropractic Adjustments: As a chiropractor, I see the body as an interconnected system. If a patient has a knee injury, it is often related to or can cause biomechanical imbalances in the hip, ankle, or spine. Chiropractic adjustments can restore proper joint mechanics, improve nerve function, and ensure the entire kinetic chain functions optimally. This reduces abnormal stress on the healing joint or tendon, creating a better mechanical environment for the PRP to work effectively.
• Nutritional and Lifestyle Support: We also support the healing process from the inside out with targeted nutritional advice to reduce systemic inflammation and provide the building blocks for tissue repair.

This integrative approach, combining advanced biologic therapies like precisely dosed PRP with foundational chiropractic care and rehabilitation, addresses both the biological deficit and the biomechanical dysfunction, leading to more complete and durable outcomes for my patients. The big takeaway is that true success in regenerative medicine comes from a deep understanding of the biologic product you are delivering and integrating it into a holistic, patient-centered treatment plan.

References

• Bansal, H., Leon, J., Pont, J. L., Wilson, D. A., Bansal, A., Agarwal, D., & Preuss, C. (2021). Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long-term clinical efficacy. Scientific Reports, 11(1), 7932. https://doi.org/10.1038/s41598-021-87302-5
• Bennell, K. L., Paterson, K. L., Metcalf, B. R., Duong, V., Emsley, R., Burns, A. W., … & Harris, A. (2021). Effect of intra-articular platelet-rich plasma vs placebo on pain, function, and structural joint changes in patients with knee osteoarthritis: The RESTORE randomized clinical trial. JAMA, 326(20), 2021–2030. https://doi.org/10.1001/jama.2021.19415
• Cole, B. J., Gole, M., Raghunath, S., MacKay, G., Murrell, W. D., & Rodeo, S. A. (2021). The role of platelet-rich plasma and other biologics in the management of rotator cuff disease. Journal of the American Academy of Orthopaedic Surgeons, 29(1), 1–11. https://doi.org/10.5435/JAAOS-D-20-00465
• Everts, P., Onishi, K., Jayaram, P., Lana, J. F., & Mautner, K. (2020). Platelet-rich plasma: New performance understandings and therapeutic considerations in 2020. International Journal of Molecular Sciences, 21(20), 7794. https://doi.org/10.3390/ijms21207794
• Giusti, I., D’Ascenzo, S., Mancò, A., Di Stefano, G., Di Paolo, S., De Silvestris, A., … & Dolo, V. (2009). Platelet-rich plasma for the treatment of refractory Achilles tendinopathy: A dose-finding study. The American Journal of Sports Medicine, 37(11), 2133–2140. https://doi.org/10.1177/0363546509341492
• James, S. L., Ali, K., Pocock, C., Ul-Islam, S., & B-L, H. (2016). A systematic review of the commercially available platelet-rich plasma systems. The Journal of Bone and Joint Surgery. British Volume, 98-B(12), 1591-1596. https://doi.org/10.1302/0301-620X.98B12.BJJ-2016-0158.R1
• Meheux, C. J., McCulloch, P. C., Lintner, D. M., Varner, K. E., & Harris, J. D. (2016). Efficacy of intra-articular platelet-rich plasma for the treatment of knee osteoarthritis: A systematic review. Arthroscopy: The Journal of Arthroscopic & Related Surgery, 32(3), 495-505. https://doi.org/10.1016/j.arthro.2015.08.005